Why Randomised Controlled Trials Are Difficult in Manual Therapy

A Gold Standard Built for a Different Kind of Treatment

The randomised, double-blind, placebo-controlled trial is widely regarded as the gold standard of clinical evidence — a design built around comparing a treatment against an indistinguishable placebo, with neither participant nor assessor aware of which was given. This design was developed primarily for pharmaceutical research, and translates awkwardly to manual therapy.

The Core Problem: You Can't Hide a Hands-On Treatment

A sugar pill can be made visually identical to an active drug; a joint mobilisation, massage or dry needling session cannot be easily disguised as something else to the person receiving it, who typically knows perfectly well whether they are being touched, moved, or needled. Methodological reviews of trials for non-pharmacological interventions have specifically highlighted this blinding challenge as a fundamental design constraint, requiring creative but imperfect solutions like sham treatments or different active comparators rather than true placebo control (Boutron et al., 2008).

Why This Doesn't Mean the Evidence Is Worthless

This does not mean manual therapy research is unreliable — it means the evidence needs to be interpreted with an understanding of what these studies can and cannot control for, and why manual therapy trials are held to, and should be evaluated against, a somewhat different methodological standard than a drug trial, rather than being dismissed for failing a bar it was never built to clear.